TREATMENT
Continuous glucose monitoring improved glycaemic control in pregnant women with diabetes and reduced infant macrosomia
| The first 150 words of the full text of this article appear below. |
H R Murphy
Dr H R Murphy, University of Cambridge, Cambridge, UK; hm386@medschl.cam.ac.uk
Does continuous glucose monitoring (CGM) improve glycaemic control in pregnant women with diabetes and reduce infant macrosomia?
Design: randomised controlled trial. Current Controlled Trials ISRCTN84461581 [controlled-trials.com] .
Allocation: concealed.
Blinding: unblinded.
Follow-up period: to delivery.
Setting: 2 diabetes antenatal clinics in the UK.
Patients: 71 pregnant women (mean age 31 y, mean gestational age 9 wks) who had type 1 diabetes (65% of women) or type 2 diabetes (35%) treated with insulin.
Intervention:
CGM plus standard antenatal care (n = 38) or standard care alone (n = 33). CGM was done every 4–6 weeks until 32 weeks of gestation. A subcutaneous sensor, attached to a portable monitor, was implanted by a nurse into the womans hip and worn for 5–7 days. The device recorded average tissue glucose concentrations every 5 minutes, but results were not available until downloaded
Faculty of Nursing, University of Alberta, Edmonton, Alberta, Canada
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
